Why the study?
Do drug eluting stents reduce the composite endpoint of MACCE compared to bare metal stents in patients with coronary artery disease?
Do drug eluting stents reduce the composite endpoint of MACCE compared to bare metal stents in patients with coronary artery disease?
While drug-eluting stents provide an early reduction in MACCE compared to bare-metal stents during the first year, this benefit does not persist, resulting in similar event rates at 14 years.
Answers are grounded in this paper and cite their sources.
Early DES-associated MACCE reduction may not persist long-term; leaves open durability of stent choice effects in CAD.
In patients with coronary artery disease, the composite endpoint of MACCE for the first year after stenting was significantly lower in patients receiving DES than those receiving BMS; however, at very long term follow-up, the event rates were similar.
No takes yet. Share an insight, caveat, or question.
Walse et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: